1.Bringing the Treatment of Atopic Eczema Into a New Era with Janus Kinase Inhibitors: A Position Statement By the Persatuan Dermatologi Malaysia
Noor Zalmy Azizan ; Adawiyah Jamil ; Chang Choong Chor ; Dawn Ambrose ; Henry Foong Boon Bee ; How Kang Nien ; Rajalingam Ramalingam ; Sabeera Begum Bt Kader Ibrahim ; Sharifah Rosniza Binti Syed Nong Chek ; Tan Wooi Chiang ; Wong Hoi Ling
Malaysian Journal of Dermatology 2022;49(Dec 2022):2-11
Abstract
Atopic eczema (AE) is a complex, chronic and recurrent inflammatory pruritic skin condition that
impacts the quality of life and exerts an economic toll on patients and their families. One of the factors
contributing to AE is the immune dysregulation of the Janus kinase-signal transducers and activators
of transcription (JAK-STAT) inflammatory pathway. This has prompted the conduct of various large
clinical trial programs to evaluate the efficacy and safety of Janus kinase inhibitors (JAK-i) for AE.
The overall and significant benefit of these drugs from clinical studies resulted in regulatory approvals
for JAK-i to treat moderate-to-severe atopic eczema. The objective of this position paper was to
evaluate the safety, efficacy and role of upadacitinib, baricitinib and abrocitinib in managing AE and
update the current recommended treatment algorithm within the 2018 Malaysian Clinical Practice
Guidelines for the Management of Atopic Eczema. The Persatuan Dermatologi Malaysia recommends
that these JAK-i can be considered as an option for systemic therapy in severe AE.
Dermatitis, Atopic--therapy
;
Janus Kinase Inhibitors
Result Analysis
Print
Save
E-mail